BARBARA SCHÜTT,MARCUS-HILLERT SCHULTZE-MOSGAU,ANDREAS KAISER
申请号：
PT14715933
公开号：
PT2983671T
申请日:
2014.04.09
申请国别(地区):
PT
年份:
2019
代理人:
摘要：
The invention is directed to a pharmaceutical composition comprising a progesterone receptor antagonist namely (11β,17β)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one at the dosage of about 0.5 to 5 mg and more particularly 2 mg. Additionally, the invention is directed to the use of the novel pharmaceutical composition for treatment of and/or prophylaxis of gynaecological diseases, such as fibroids of the uterus (myomas, uterine leiomyoma), endometriosis or excessive menstrual bleeds, and method for obtaining such composition and oral dosage form.
